Natera Inc
NASDAQ:NTRA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
55.01
169.36
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Natera Inc
Natera Inc
Net Issuance of Debt
Natera Inc
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Natera Inc
NASDAQ:NTRA
|
Net Issuance of Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Issuance of Debt
$9.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Issuance of Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Issuance of Debt
-$360m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Issuance of Debt
-$42.5m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Issuance of Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Natera Inc
Glance View
Natera Inc. is a leading genomics company that specializes in genetic testing and precision medicine, aiming to revolutionize healthcare through advanced DNA analysis. Founded in 2004 and headquartered in Austin, Texas, Natera focuses on reproductive health, oncology, and organ transplant management, providing invaluable insights that help doctors make informed decisions for their patients. Its flagship products include non-invasive prenatal testing (NIPT), which has gained significant traction for its ability to assess fetal health with remarkable accuracy, along with tests for hereditary cancer risk and monitoring treatment response in cancer patients. By harnessing the power of next-generation sequencing and machine learning, Natera is positioned to disrupt traditional medical practices and improve patient outcomes. Investors looking at Natera will find a company poised for growth amid increasing demand for genetic testing and personalized medicine. The company benefits from a robust pipeline and an expanding customer base, bolstered by strategic collaborations with healthcare providers and insurance companies. As awareness of genetic testing continues to rise, Natera's innovative solutions could capture substantial market share, particularly in oncology, where early detection can dramatically impact treatment efficacy and survival rates. With strong financial backing, a commitment to research and development, and a vision to elevate the standard of care through data-driven insights, Natera represents a compelling opportunity for those seeking to invest in the future of healthcare.
You don't have any saved screeners yet
